3-hydroxyquinazoline derivatives, analogues of erastin, induce ferroptosis in colorectal cancer cells

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

In recent years, significant progress has been achieved in the treatment of patients with colon cancer, but in most cases treatment is accompanied by the development of drug resistance. Recently discovered iron-dependent cell death, ferroptosis, makes it a promissing therapeutic target to reduce the recurrence rates. In this study we have examined the effect of 3-hydoxyquinazoline derivatives on ferroptosis induction in two colon cancer cells HCT-116 and DLD-1. The ferroptotic cell death was identified by the level of lipid peroxidation. The level of lipid peroxidation in HCT-116 cells induced by some compounds approached the activity of the reference drug erastin. This scenario changed significantly when the ferroptosis induction was studied in DLD-1 cells. Two 3-hydroxyquinazoline derivatives induced levels of lipid peroxidation in DLD-1 cells that exceeded those of erastin. The preliminary results obtained suggest that three new compounds can be considered as an antitumor agent for the treatment of colon cancer, and also indicate the prospects of further searching for ferroptosis inducers among 3-hydroxyquinazoline derivatives.

全文:

受限制的访问

作者简介

V. Osipov

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

编辑信件的主要联系方式.
Email: ovn65@yandex.ru
俄罗斯联邦, Kashirskoe shosse 24, Moscow, 115478

A. Vartanyan

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
俄罗斯联邦, Kashirskoe shosse 24, Moscow, 115478

D. Khochenkov

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
俄罗斯联邦, Kashirskoe shosse 24, Moscow, 115478

D. Gusev

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
俄罗斯联邦, Kashirskoe shosse 24, Moscow, 115478

O. Fateenkova

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)

Email: ovn65@yandex.ru
俄罗斯联邦, ul. Trubetskaya 8/2, Moscow, 119991

D. Khachatryan

National Research Center “Kurchatov Institute”

Email: ovn65@yandex.ru
俄罗斯联邦, pl. Akad. Kurchatova 1, Moscow, 123182

L. Borisova

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
俄罗斯联邦, Kashirskoe shosse 24, Moscow, 115478

参考

  1. Fabregas J.C., Ramnaraign B., George T.J. // Clin. Colorectal Cancer. 2022. V. 21. P. 198–203. https://doi.org/10.1016/j.clcc.2022.05.006
  2. Grazzini G., Danti G., Chiti G., Giannessi C., Pradella S., Miele V. // Diagnostics (Basel). 2023. V. 13. P. 2104–2115. https://doi.org/10.3390/diagnostics13122104
  3. Afrăsânie V.A., Marinca M.V., Alexa-Stratulat T., Gafton B., Păduraru M., Adavidoaiei A.M., Miron L., Rusu C. // Radiol. Oncol. 2019. V. 53. P. 265–274. https://doi.org/10.2478/raon-2019-0033
  4. Kozovska Z., Gabrisova V., Kucerova L. // Biomed. Pharmacother. 2014. V. 68. P. 911–916. https://doi.org/10.1016/j.biopha.2014.10.019
  5. Van der Jeught K., Xu H.C., Li Y.J., Lu X.B., Ji G. // World J. Gastroenterol. 2018. V. 24. P. 3834–3848. https://doi.org/10.3748/wjg.v24.i34.3834
  6. Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., Morrison B., 3rd, Stockwell B.R. // Cell. 2012. V. 149. P. 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
  7. Negri F., Bottarelli L., de’Angelis G.L., Gnetti L. // Int. J Mol. Sci. 2022. V. 23. P. 4120–4128. https://doi.org/10.3390/ijms23084120
  8. Zhang C., Liu X., Jin S., Chen Y., Guo R. // Mol. Cancer. 2022. V. 21. P. 47–59. https://doi.org/10.1186/s12943-022-01530-y
  9. Prutki M., Poljak-Blazi M., Jakopovic M., Tomas D., Stipancic I., Zarkovic N. // Cancer Lett. 2006. V. 238. P. 188–96. https://doi.org/10.1016/j.canlet.2005.07.001
  10. Demir H., Beypinar I., Urvay S., Davarci S.E., Baykara M. // Eur. Rev. Med. Pharmacol. Sci. 2021. V. 25. P. 6473–6479. https://doi.org/10.26355/eurrev_202111_27091
  11. Xu T., Ding W., Ji X., Ao X., Liu Y., Yu W., Wang J. // J. Cell Mol Med. 2019. V. 23. P. 4900–4912. https://doi.org/10.1111/jcmm.14511
  12. Galluzzi L., Vitale I., Warren S., Adjemian S., Agostinis P., Martinez A.B., Chan T.A., Coukos G., Demaria S., Deutsch E., Draganov D., Edelson R.L., Formenti S.C., Fucikova J., Gabriele L., Gaipl U.S., Gameiro S.R., Garg A.D., Golden E., Han J., Harrington K.J., Hemminki A., Hodge J.W., Hossain D.M.S., Illidge T., Karin M., Kaufman H.L., Kepp O., Kroemer G., Lasarte J.J., Loi S., Lotze M.T., Manic G., Merghoub T., Melcher A.A., Mossman K.L., Prosper F., Rekdal Ø., Rescigno M., Riganti C., Sistigu A., Smyth M.J., Spisek R., Stagg J., Strauss B.E., Tang D., Tatsuno K., van Gool S.W., Vandenabeele P., Yamazaki T., Zamarin D., Zitvogel L., Cesano A., Marincola F.M. // J. Immunother. Cancer. 2020. V. 8. P. e000337. https://doi.org/10.1136/jitc-2019-000337
  13. Sprooten J., De Wijngaert P., Vanmeerbeerk I., Martin S., Vangheluwe P., Schlenner S., Krysko D.V., Parys J.B., Bultynck G., Vandenabeele P., Garg A.D. // Cells. 2020. V. 9. P. 1823. https://doi.org/10.3390/cells9081823
  14. Wiernicki B., Maschalidi S., Pinney J., Adjemian S., Vanden Berghe T., Ravichandran K.S., Vandenabeele P. // Nat. Commun. 2022. V. 13. P. 3676. https://doi.org/10.1038/s41467-022-31218-2
  15. Борисова Л.М., Осипов В.Н., Гусев Д.В. Голубева И.С., Киселева М.П., Вартанян А.А. // Рос. биотерапевтич. журнал. 2021. Т. 20. С. 67–73. https://doi.org/10.17650/1726-9784-2021-20-1-67-73
  16. Борисова Л.М., Осипов В.Н., Голубева И.С., Киселева М.П., Хоченков Д.А., Вартанян А.А. // Усп. мол. онкологии. 2022. Т. 9. С. 48–56. https://doi.org/10.17650/2313-805X-2022-9-1-48-56
  17. Wang Y., Wu X., Ren Z., Li Y., Zou W., Chen J., Wang H. // Drug Resist. Updat. 2023. V. 66. P. 100916. https://doi.org/10.1016/j.drup.2022.100916
  18. Вартанян А.А., Осипов В.Н., Хоченков Д.А., Гусев Д.В., Борисова Л.М. // Патент RU 2722308 С1, опубл. 28.05.2020.
  19. Trainer D.L., Kline T., McCabe F.L., Faucette L.F., Feild J., Chaikin M., Anzano M., Rieman D., Hoffstein S., Li D.J., Gennaro D., Buscarino C., Lynch M., Poste G., Greig R. // Int. J. Cancer. 1988. V. 41. P. 287–296. https://doi.org/10.1002/ijc.2910410221
  20. Chen S.K., Ma W.Q., Yan Z.B., Zhang F.M., Wang S.H., Nu Y.Q., Zhang X.M., Tian J.M. // J. Am. Chem. Soc. 2018. V. 140. P. 10099–10103. https://doi.org/10.3389/fphar.2017.00992
  21. Martinez A.M., Kim A., Yang W.S. // Methods Mol. Biol. 2020. V. 2108. P. 125–130. https://doi.org/10.1007/978-1-0716-0247-8_11
  22. Sakata S., Larson D.W. // Surg. Oncol. Clin. N. Am. 2022. V. 31. P. 255–264. https://doi.org/10.1016/j.soc.2021.11.006
  23. Zhang C., Liu X., Jin S., Chen Y., Guo R. // Mol. Cancer. 2022. V. 21. P. 47–58. https://doi.org/10.1186/s12943-022-01530-y

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Effect of compound (VIIa) on the induction of ferroptosis in HCT-116 cells: (a) – control – cell growth with 5% DMSO; (b) – cell growth with 1/3 IC50 erastin; (c) – cell growth with 1/3 IC50 of compound (VIIa). Scale bar – 100 µm.

下载 (151KB)
索引源数据
3. Fig. 2. Quantitative characteristics of the intensity of lipid peroxidation in HCT-116 and DLD-1 cells. K – fluorescence intensity induced by erastin, 1–7 – compounds (VIIa–g), respectively. Data are presented as mean ± standard deviation, p < 0.05.

下载 (69KB)
索引源数据
4. Scheme 1. Synthesis of 3-hydroxyquinozaline derivatives. Reagents and conditions: i – CH2Cl2/H2O, thiophosgene; ii – AcONa, H2O; iii – NaOH, NH2OH . HCl, H2O; iv – NH2NH2 . H2O, ethanol; v – acetylacetone, ethanol; vi – benzyl chloroacetate, K2CO3, DMF.

下载 (94KB)
索引源数据
5. Tab. 1, fig. 1

下载 (23KB)
索引源数据
6. Tab. 1, fig. 2

下载 (23KB)
索引源数据
7. Tab. 1, fig. 3

下载 (23KB)
索引源数据
8. Tab. 1, fig. 4

下载 (23KB)
索引源数据
9. Tab. 1, fig. 5

下载 (22KB)
索引源数据
10. Tab. 1, fig. 6

下载 (22KB)
索引源数据
11. Tab. 1, fig. 7

下载 (23KB)
索引源数据
12. Tab. 1, fig. 8

下载 (27KB)
索引源数据

版权所有 © Russian Academy of Sciences, 2024